Identification | Back Directory | [Name]
(R)-5-HydroxyMethyl Tolterodine | [CAS]
207679-81-0 | [Synonyms]
5-HM 5-HMT PNU 200577 PNU-200577 Desfesoterodine Fesoterodine Diol Fesoterodine Diol (R)-Isomer (R)-5-Hydroxymethyl tolterodine Fesoterodine fumarate Intermediate 2 Tolterodine 5-Hydroxymethyl (R)-Isomer 5-hydroxyMethyl tolterodine (PNU 200577) (R)-5-HydroxyMethyl Tolterodine USP/EP/BP Fesoterodine Impurity 1(Fesoterodine Diol) 5-hydroxyMethyl Tolterodine (PNU 200577, 5-HMT, 5-HM) R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol (R)-2-(3-(diisopropylaMino)-1-phenylpropyl)-4-(hydroxyMethyl)phenol (5-HMT) 3-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxybenzenemethanol Benzenemethanol, 3-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy- | [Molecular Formula]
C22H31NO2 | [MDL Number]
MFCD09264524 | [MOL File]
207679-81-0.mol | [Molecular Weight]
341.49 |
Chemical Properties | Back Directory | [Melting point ]
68-72°C | [Boiling point ]
490.7±45.0 °C(Predicted) | [density ]
1.060±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.61±0.48(Predicted) | [color ]
Off-White to Pale Yellow |
Hazard Information | Back Directory | [Chemical Properties]
Pale Yellow Solid | [Uses]
(R)-5-HydroxyMethyl Tolterodine is a metabolite of Tolterodine (T535800), a muscarinic receptor antagonist used in the treatment of urinary incontinence.
| [Uses]
A metabolite of Tolterodine, a muscarinic receptor antagonist used in the treatment of urinary incontinence. | [Definition]
ChEBI: Desfesoterodine is a diarylmethane. | [in vivo]
Desfesoterodine (PNU-200577; 5-Hydroxymethyl Tolterodine; 0.1 and 1 mg/kg; IV) significantly increases bladder compliance after moderate and high doses[4].
In vivo, Desfesoterodine is significantly more potent at suppressing acetylcholine-induced urinary bladder contraction than electrically induced salivation in the anaesthetised cat (ID50=15 and 40 nmol/kg, respectively) [1].
Animal Model: | Female Sprague Dawley rats at ages 9 to 11 weeks weighing 180 to 250 g[4] | Dosage: | 0.1 and 1 mg/kg | Administration: | IV; single imidafenacin administration | Result: | Significantly increased bladder compliance after moderate and high doses.
|
| [storage]
Store at -20°C |
|
|